Argomenti trattati
The second edition of HITLAB New York City Health Innovation Week convenes leaders across healthcare, technology, and investment to examine emerging trends that are reshaping patient care. This conference uses a mix of panels, showcases, and structured networking to move conversations from theory into practice, offering attendees a chance to compare evidence, commercialization strategies, and market traction in an interactive setting. As the event returns for its second year, participants can expect deep dives into how digital health products are validated, scaled, and financed.
Joining the program from the legal and investment side is Craig Kenesky, partner at Brown Rudnick. His involvement reflects the growing importance of legal and financial frameworks in early-stage health technology. Over two days of programming he will lead discussion on funding dynamics and then address how a deliberate intellectual property approach can influence valuation and investor perceptions. These sessions are aimed at founders, investors, and advisors seeking practical guidance in a data-driven healthcare market.
Leading the investment and growth conversation
On May 6, Kenesky will chair the symposium titled Investment, Funding & Startup Growth, a focused session that interrogates the signals investors rely on when appraising health tech opportunities. Panelists will explore the balance between clinical validation, user adoption, and business metrics, and how each contributes to perceived value. The program will also discuss go-to-market priorities and the operational changes founders must navigate to move from pilot to scale. Within this context, the term traction will be clarified as measurable milestones such as patient engagement, recurring revenue, or confirmed payer pathways that substantiate growth claims.
How evidence and traction shape funding decisions
Investors increasingly expect concrete proof before allocating capital, a trend that emerged as digital health matured. In practice, that means evidence beyond concept: validated clinical outcomes, reproducible pilot results, and sustained user behavior. The session will examine the spectrum of acceptable evidence, from early feasibility data to payer-backed reimbursement agreements, and consider how each level affects risk assessment. Panelists will also address common founder missteps, including overreliance on promising prototypes without a clear path to real-world adoption, and will recommend data strategies that meet investor expectations while preserving agility.
Why IP strategy matters to valuation
On May 7, Kenesky will present on How IP Strategy Drives Startup Valuation and Investor Confidence, unpacking how legal positioning can materially affect fundraising outcomes. Here, intellectual property is framed not merely as patents but as a composite of patents, trade secrets, licensing arrangements, and freedom-to-operate assessments that together create defensibility. The talk will highlight how a coherent IP plan can reduce perceived execution risk, clarify exit scenarios for investors, and translate technical differentiation into tangible value during due diligence.
Translating legal strategy into investment-ready assets
Founders will gain practical insights on aligning product roadmaps with patent strategy, choosing when to publish versus protect, and negotiating licenses that preserve optionality. For investors, Kenesky’s discussion will illustrate how effective IP work streams—such as early patent filings, targeted claim drafting, and clear ownership records—streamline diligence and support higher valuation multiples. The session will also explore transactional tools like staged licensing and strategic partnerships that can accelerate commercialization while maintaining upside for existing stakeholders.
Practical outcomes for attendees
Across both sessions, attendees can expect outcome-oriented guidance: concrete metrics to present to potential backers, a checklist for building reproducible evidence, and legal milestones that enhance investor confidence. The conference’s mix of panels and showcases provides an environment where founders can test narratives and hear immediate feedback from investors and clinicians. In addition to formal programming, the event’s networking format fosters serendipitous connections that often lead to pilot agreements, advisory relationships, or funding conversations. For those eager to explore the intersection of finance, law, and technology in healthcare, these sessions offer a compact, actionable roadmap.
For more information about schedules, speakers, and how to attend, visit the event page. Whether you’re a founder refining a pitch, an investor vetting new opportunities, or an advisor helping startups scale, the discussions chaired and led by Craig Kenesky during HITLAB New York City Health Innovation Week are designed to translate complex topics into actionable next steps.